Details of the Drug Combinations | DrugMAP

General Information of This Drug (ID: DMCMJRA)

Drug Name

EGF816 DMCMJRA

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 3	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
EGF816 + Capmatinib	DCAP2E0	Capmatinib	Non Small Cell Lung Cancer	[2]
EGF816 + LEE011	DCJPVYX	LEE011	EGFR-mutant Non-small Cell Lung Cancer	[3]
Gefitinib + EGF816	DCFP9A7	Gefitinib	EGFR-mutant Non-small Cell Lung Cancer	[3]
Trametinib + EGF816	DCOFJW9	Trametinib	EGFR-mutant Non-small Cell Lung Cancer	[3]
Gefitinib + EGF816	DC5PKWD	Gefitinib	Lung Cancer	[4]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02335944) Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
3	ClinicalTrials.gov (NCT03333343) Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
4	ClinicalTrials.gov (NCT03292133) A Study of EGF816 and Gefitinib in TKI-nave EGFR-mutant Non-Small Cell Lung Cancer